Does osteoporosis therapy invalidate FRAX for fracture prediction?

Journal of Bone and Mineral Research

Volumn 27, Issue 6, 2012, Pages 1243-1251

  Leslie, William D ^a   Lix, Lisa M ^b   Johansson, Helena ^c   Oden, Anders ^c   McCloskey, Eugene ^d   Kanis, John A ^e  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c Consulting Statistician ^*  (Sweden)

^d NORTHERN GENERAL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

BONE DENSITOMETRY; EPIDEMIOLOGY; OSTEOPOROSIS; POPULATION STUDIES; TREATMENTS

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; RALOXIFENE; SALCATONIN;

AGED; ARTICLE; BONE DENSITY; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT;

AGED; AREA UNDER CURVE; CANADA; COHORT STUDIES; FEMALE; FEMORAL NECK FRACTURES; HUMANS; MIDDLE AGED; OSTEOPOROTIC FRACTURES; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; ROC CURVE;

EID: 84859441811     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1582     Document Type: Article

References (43)

1. Elffors L., Are osteoporotic fractures due to osteoporosis? Impacts of a frailty pandemic in an aging world. Aging (Milano). 1998; 10: 191-204.
2. Keen RW., Burden of osteoporosis and fractures. Curr Osteoporos Rep. 2003; 1: 66-70.
3. Lips P, van Schoor NM., Quality of life in patients with osteoporosis. Osteoporos Int. 2005; 16: 447-55.
4. Ström O, Borgström F, Kanis JA, Compston J, Cooper C, McCloskey EV, Jönsson B., Osteoporosis: burden, health care provision and opportunities in the EU. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2011 DOI: 10.1007/s11657-011-0060-1.
5. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J., Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008; 148: 197-213.
6. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD., 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010; 182: 1864-73.
7. Rizzoli R, Reginster JY, Boonen S, Breart G, ez-Perez A, Felsenberg D, Kaufman JM, Kanis JA, Cooper C., Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int. 2011; 89: 91-104.
8. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Gluer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ III, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N., The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007; 18: 1033-46.
9. Leslie WD, Morin S, Lix LM., A before-and-after study of fracture risk reporting and osteoporosis treatment initiation. Ann Intern Med. 2010; 153: 580-6.
10. Dawson-Hughes B, Tosteson AN, Melton LJ III, Baim S, Favus MJ, Khosla S, Lindsay RL., Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008; 19: 449-58.
11. Dawson-Hughes B., A revised clinician's guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab. 2008; 93: 2463-5.
12. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A., Case finding for the management of osteoporosis with FRAX((R))-assessment and intervention thresholds for the UK. Osteoporos Int. 2008; 19: 1395-408.
13. Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, wson-Hughes B, El-Hajj FG, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV., Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011 [Epub ahead of print].
14. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM., Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002; 112: 281-9.
15. Seeman E., Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?. Bone. 2007; 41: 308-17.
16. Leslie WD, Lix LM, Langsetmo L, Berger C, Goltzman D, Hanley DA, Adachi JD, Johansson H, Oden A, McCloskey E, Kanis JA., Construction of a FRAX((R)) model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int. 2011; 22: 817-27.
17. Leslie WD, MacWilliam L, Lix L, Caetano P, Finlayson GS., A population-based study of osteoporosis testing and treatment following introduction of a new bone densitometry service. Osteoporos Int. 2005; 16: 773-82.
18. Leslie WD, Caetano PA, MacWilliam LR, Finlayson GS., Construction and validation of a population-based bone densitometry database. J Clin Densitom. 2005; 8: 25-30.
19. Binkley N, Kiebzak GM, Lewiecki EM, Krueger D, Gangnon RE, Miller PD, Shepherd JA, Drezner MK., Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. J Bone Miner Res. 2005; 20: 195-201.
20. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ III, Khaltaev N., A reference standard for the description of osteoporosis. Bone. 2008; 42: 467-75.
21. Leslie WD, Ward LM., Bone density monitoring with the total hip site: time for a re-evaluation?. J Clin Densitom. 2004; 7: 269-74.
22. Roos NP, Shapiro E., Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system. Med Care. 1999; 37: JS10-4.
23. Leslie WD, Tsang JF, Caetano PA, Lix LM., Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab. 2007; 92: 77-81.
24. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Oslo (Norway): WHO Collaborating Centre for Drug Statistics Methodology; 2005.
25. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA., Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res. 2010; 25: 2350-8.
26. Leslie WD, Berger C, Langsetmo L, Lix LM, Adachi JD, Hanley DA, Ioannidis G, Josse RG, Kovacs CS, Towheed T, Kaiser S, Olszynski WP, Prior JC, Jamal S, Kreiger N, Goltzman D., Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int. 2011; 22 (6): 1873-83.
27. Fraser LA, Langsetmo L, Berger C, Ioannidis G, Goltzman D, Adachi JD, Papaioannou A, Josse R, Kovacs CS, Olszynski WP, Towheed T, Hanley DA, Kaiser SM, Prior J, Jamal S, Kreiger N, Brown JP, Johansson H, Oden A, McCloskey E, Kanis JA, Leslie WD., Fracture prediction and calibration of a Canadian FRAX(R) tool: a population-based report from CaMos. Osteoporos Int. 2011; 22: 829-37.
28. Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ III., The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int. 2010; 21: 41-52.
29. Ettinger B, Black DM, wson-Hughes B, Pressman AR, Melton LJ III., Updated fracture incidence rates for the US version of FRAX. Osteoporos Int. 2010; 21: 25-33.
30. Kozyrskyj AL, Mustard CA., Validation of an electronic, population-based prescription database. Ann Pharmacother. 1998; 32: 1152-7.
31. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-33.
32. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD., A note on competing risks in survival data analysis. Br J Cancer. 2004; 91: 1229-35.
33. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P., Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; 23 (1): CD001155.
34. Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P., Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; 23 (1): CD004523.
35. Boonen S, Laan RF, Barton IP, Watts NB., Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int. 2005; 16: 1291-8.
36. Feldstein AC, Weycker D, Nichols GA, Oster G, Rosales G, Boardman DL, Perrin N., Effectiveness of bisphosphonate therapy in a community setting. Bone. 2009; 44: 153-9.
37. Curtis JR, Mudano AS, Solomon DH, Xi J, Melton ME, Saag KG., Identification and validation of vertebral compression fractures using administrative claims data. Med Care. 2009; 47: 69-72.
38. Jean S, Candas B, Belzile E, Morin S, Bessette L, Dodin S, Brown JP., Algorithms can be used to identify fragility fracture cases in physician-claims databases. Osteoporos Int. 2012; 23: 483-501.
39. McCloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K, Jalava T, Kanis JA., Ten-year fracture probability identifies women who will benefit from clodronate therapy-additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int. 2009; 20: 811-7.
40. Kanis JA, Johansson H, Oden A, McCloskey EV., Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone. 2009; 44: 1049-54.
41. Kanis JA, Johansson H, Oden A, McCloskey EV., A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone. 2010; 47: 729-35.
42. Kanis JA, Johansson H, Oden A, McCloskey EV., A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R)). Osteoporos Int. 2011; 22: 2347-55.
43. McCloskey EV, Lewiecki EM, Kanis JA, Johansen H, Johansson H, Oden A, Austin M, Siris E, Wang A, Libanati C, Chapurlat R, Lorenc R., Denosumab reduces the risk of clinical osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX®. Osteoporos Int. 2011; 22: S103.